Loading
Obesity / Orforglipron / Overweight · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registration record for a Phase 3, double-arm randomized trial of the GLP-1 receptor agonist orforglipron versus placebo in adults with obesity or overweight and weight-related comorbidities. No efficacy or safety results are posted in this registry record, so the evidence base is not yet available for clinical interpretation.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Obesity, Overweight, Overweight or Obesity; age from 18 Years. Intervention: 6 mg Orforglipron; 12 mg Orforglipron; 36 mg Orforglipron. Compared with: Placebo — Placebo Comparator. n = 3,127. 138 sites across 10 countries.
This is a registration record for a Phase 3, double-arm randomized trial of the GLP-1 receptor agonist orforglipron versus placebo in adults with obesity or overweight and weight-related comorbidities. No efficacy or safety results are posted in this registry record, so the evidence base is not yet available for clinical interpretation.
No efficacy, safety, or outcome data are reported in this registry record.
The source did not state who this applies to in practice.
This is a clinical trial registry record with no results reported; it describes a planned Phase 3 interventional study that is active but not yet recruiting or has completed enrollment without posted outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05869903). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 3127 participants (ACTUAL). Conditions: Obesity, Overweight, Overweight or Obesity. Interventions: DRUG: Orforglipron; DRUG: Placebo. Primary outcome measures: Percent Change From Baseline in Body Weight (Primary Treatment Period) , Baseline, Week 72. Brief summary: This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.